(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.28%.
Rallybio's earnings in 2026 is -$7,817,000.On average, 4 Wall Street analysts forecast RLYB's earnings for 2026 to be -$24,880,581, with the lowest RLYB earnings forecast at -$28,702,127, and the highest RLYB earnings forecast at -$20,472,001. On average, 3 Wall Street analysts forecast RLYB's earnings for 2027 to be -$19,454,759, with the lowest RLYB earnings forecast at -$18,691,827, and the highest RLYB earnings forecast at -$20,026,958.
In 2028, RLYB is forecast to generate -$16,860,791 in earnings, with the lowest earnings forecast at -$16,199,584 and the highest earnings forecast at -$17,356,697.